Identification of an aminothiazole with antifungal activity against intracellular Histoplasma capsulatum

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4349-4359

  Edwards, Jessica A ^a   Kemski, Megan M ^a   Rappleye, Chad A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTHIAZOLE; ANTIFUNGAL AGENT; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; DRUG IDENTIFICATION; FUNGUS GROWTH; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HOST CELL; LIQUID CULTURE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; YEAST;

ANIMALS; ANTIFUNGAL AGENTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, REPORTER; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HISTOPLASMA; HUMANS; LAC OPERON; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; SMALL MOLECULE LIBRARIES; THIAZOLES;

EID: 84882414466     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00459-13     Document Type: Article

References (53)

1. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. 2002. The direct cost and incidence of systemic fungal infections. Value Health 5:26-34.
2. Finkelstein A, Holz R. 1973. Aqueous pores created in thin lipid membranes by the polyene antibiotics nystatin and amphotericin B. Membranes 2:377-408.
3. Palacios DS, Dailey I, Siebert DM, Wilcock BC, Burke MD. 2011. Synthesis-enabled functional group deletions reveal key underpinnings of amphotericin B ion channel and antifungal activities. Proc. Natl. Acad. Sci. U. S. A. 108:6733-6738.
4. Hsuchen CC, Feingold DS. 1973. Selective membrane toxicity of the polyene antibiotics: studies on natural membranes. Antimicrob. Agents Chemother. 4:316-319.
5. Moen MD, Lyseng-Williamson KA, Scott LJ. 2009. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69:361-392.
6. Vanden Bossche H, Willemsens G, Marichal P. 1987. Anti-Candida drugs-the biochemical basis for their activity. Crit. Rev. Microbiol. 15: 57-72.
7. Georgopapadakou NH, Walsh TJ. 1996. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. 40:279-291.
8. Korashy HM, Shayeganpour A, Brocks DR, El-Kadi AO. 2007. Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines. Toxicol. Sci. 97: 32-43.
9. Girois SB, Chapuis F, Decullier E, Revol BG. 2006. Adverse effects of antifungal therapies in invasive fungal infections: review and metaanalysis. Eur. J. Clin. Microbiol. Infect. Dis. 25:138-149.
10. Hage CA, Connolly P, Horan D, Durkin M, Smedema M, Zarnowski R, Smith P, Wheat LJ. 2011. Investigation of the efficacy of micafungin in the treatment of histoplasmosis using two North American strains of Histoplasma capsulatum. Antimicrob. Agents Chemother. 55:4447-4450.
11. Maligie MA, Selitrennikoff CP. 2005. Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob. Agents Chemother. 49:2851-2856.
12. Messer SA, Jones RN, Moet GJ, Kirby JT, Castanheira M. 2010. Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008). J. Clin. Microbiol. 48:2984-2987.
13. Edwards LB, Acquaviva FA, Livesay VT, Cross FW, Palmer CE. 1969. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am. Rev. Respir. Dis. 99(Suppl):1-132.
14. Holbrook ED, Edwards JA, Youseff BH, Rappleye CA. 2011. Definition of the extracellular proteome of pathogenic-phase Histoplasma capsulatum. J. Proteome Res. 10:1929-1943.
15. Hwang L, Hocking-Murray D, Bahrami AK, Andersson M, Rine J, Sil A. 2003. Identifying phase-specific genes in the fungal pathogen Histoplasma capsulatum using a genomic shotgun microarray. Mol. Biol. Cell 14: 2314-2326.
16. Nguyen VQ, Sil A. 2008. Temperature-induced switch to the pathogenic yeast form of Histoplasma capsulatum requires Ryp1, a conserved transcriptional regulator. Proc. Natl. Acad. Sci. U. S. A. 105:4880-4885.
17. Patel JB, Batanghari JW, Goldman WE. 1998. Probing the yeast phasespecific expression of the CBP1 gene in Histoplasma capsulatum. J. Bacteriol. 180:1786-1792.
18. Rippon JW. 1988. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes, 3rd ed, p 381-423. WB Saunders Co, Philadelphia, PA.
19. Chu JH, Feudtner C, Heydon K, Walsh TJ, Zaoutis TE. 2006. Hospitalizations for endemic mycoses: a population-based national study. Clin. Infect. Dis. 42:822-825.
20. Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA. 2007. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 45:807-825.
21. Marion CL, Rappleye CA, Engle JT, Goldman WE. 2006. An alpha-(1,4)-amylase is essential for alpha-(1,3)-glucan production and virulence in Histoplasma capsulatum. Mol. Microbiol. 62:970-983.
22. Worsham PL, Goldman WE. 1988. Quantitative plating of Histoplasma capsulatum without addition of conditioned medium or siderophores. J. Med. Vet. Mycol. 26:137-143.
23. Fothergill AW. 2012. Antifungal susceptibility testing: Clinical Laboratory and Standards Institute (CLSI) methods, p 65-74. In Hall GS (ed), Interactions of yeasts, moulds, and antifungal agents: how to detect resistance. Humana Press, Totowa, NJ.
24. Fadden P, Huang KH, Veal JM, Steed PM, Barabasz AF, Foley B, Hu M, Partridge JM, Rice J, Scott A, Dubois LG, Freed TA, Silinski MA, Barta TE, Hughes PF, Ommen A, Ma W, Smith ED, Spangenberg AW, Eaves J, Hanson GJ, Hinkley L, Jenks M, Lewis M, Otto J, Pronk GJ, Verleysen K, Haystead TA, Hall SE. 2010. Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem. Biol. 17:686-694.
25. Marjanovic J, Chalupska D, Patenode C, Coster A, Arnold E, Ye A, Anesi G, Lu Y, Okun I, Tkachenko S, Haselkorn R, Gornicki P. 2010. Recombinant yeast screen for new inhibitors of human acetyl-CoA carboxylase 2 identifies potential drugs to treat obesity. Proc. Natl. Acad. Sci. U. S. A. 107:9093-9098.
26. Edwards JA, Zemska O, Rappleye CA. 2011. Discovery of a role for Hsp82 in Histoplasma virulence through a quantitative screen for macrophage lethality. Infect. Immun. 79:3348-3357.
27. Kueng W, Silber E, Eppenberger U. 1989. Quantification of cells cultured on 96-well plates. Anal. Biochem. 182:16-19.
28. Edwards JA, Alore EA, Rappleye CA. 2011. The yeast-phase virulence requirement for alpha-glucan synthase differs among Histoplasma capsulatum chemotypes. Eukaryot. Cell 10:87-97.
29. LeMonte AM, Washum KE, Smedema ML, Schnizlein-Bick C, Kohler SM, Wheat LJ. 2000. Amphotericin B combined with itraconazole or fluconazole for treatment of histoplasmosis. J. Infect. Dis. 182:545-550.
30. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73.
31. Goh EB, Yim G, Tsui W, McClure J, Surette MG, Davies J. 2002. Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics. Proc. Natl. Acad. Sci. U. S. A. 99:17025-17030.
32. Hughes JP, Rees S, Kalindjian SB, Philpott KL. 2011. Principles of early drug discovery. Br. J. Pharmacol. 162:1239-1249.
33. Sebghati TS, Engle JT, Goldman WE. 2000. Intracellular parasitism by Histoplasma capsulatum: fungal virulence and calcium dependence. Science 290:1368-1372.
34. Bohse ML, Woods JP. 2007. RNA interference-mediated silencing of the YPS3 gene of Histoplasma capsulatum reveals virulence defects. Infect. Immun. 75:2811-2817.
35. Youseff BH, Holbrook ED, Smolnycki KA, Rappleye CA. 2012. Extracellular superoxide dismutase protects Histoplasma yeast cells from hostderived oxidative stress. PLoS Pathog. 8:e1002713. doi:10.1371/journal .ppat.1002713.
36. Wang JL, Chang CH, Young-Xu Y, Chan KA. 2010. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob. Agents Chemother. 54:2409-2419.
37. Espinel-Ingroff A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
38. Graybill JR, Najvar LK, Montalbo EM, Barchiesi FJ, Luther MF, Rinaldi MG. 1998. Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob. Agents Chemother. 42:151-153.
39. Kohler S, Wheat LJ, Connolly P, Schnizlein-Bick C, Durkin M, Smedema M, Goldberg J, Brizendine E. 2000. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother. 44:1850-1854.
40. Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M. 2003. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob. Agents Chemother. 47:1376-1381.
41. Finquelievich J, Landaburu MF, Pinoni V, Iovannitti CA. 2011. Determination of the therapeutic activity of caspofungin compared with the amphotericin B in an animal experimental model of histoplasmosis in hamster (Mesocrisetus auratus). Rev. Iberoam. Micol. 28:155-158.
42. Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, Lynch K, Brubaker R, Walzer PD. 2010. Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One 5:e8524. doi:10.1371/journal.pone.0008524.
43. Espinel-Ingroff A, Fothergill A, Fuller J, Johnson E, Pelaez T, Turnidge J. 2011. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob. Agents Chemother. 55:2855-2859.
44. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69:45-50.
45. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176.
46. Wheat J, Marichal P, Vanden Bossche H, Le Monte A, Connolly P. 1997. Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob. Agents Chemother. 41:410-414.
47. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC. 2006. 2-Aminothiazole as a novel kinase inhibitor template. Structureactivity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6- [4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1, 3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 49:6819-6832.
48. Hom RK, Bowers S, Sealy JM, Truong AP, Probst GD, Neitzel ML, Neitz RJ, Fang L, Brogley L, Wu J, Konradi AW, Sham HL, Toth G, Pan H, Yao N, Artis DR, Quinn K, Sauer JM, Powell K, Ren Z, Bard F, Yednock TA, Griswold-Prenner I. 2010. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg. Med. Chem. Lett. 20:7303-7307.
49. Lu J, Shi M, Shoichet MS. 2009. Click chemistry functionalized polymeric nanoparticles target corneal epithelial cells through RGD-cell surface receptors. Bioconjug. Chem. 20:87-94.
50. Sams AG, Mikkelsen GK, Larsen M, Langgard M, Howells ME, Schroder TJ, Brennum LT, Torup L, Jorgensen EB, Bundgaard C, Kreilgard M, Bang-Andersen B. 2011. Discovery of phosphoric acid mono-{2-[(E/ Z)-4-(3,3-dimethyl-butyrylamino) -3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist. J. Med. Chem. 54:751-764.
51. Borelli C, Schaller M, Niewerth M, Nocker K, Baasner B, Berg D, Tiemann R, Tietjen K, Fugmann B, Lang-Fugmann S, Korting HC. 2008. Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi. Chemotherapy 54:245-259.
52. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed, CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
53. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed, CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.